Related Experiment Video
Updated: Jan 18, 2026
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
Infant protection from invasive Haemophilus influenzae type b disease using the PRP-OMPC conjugate vaccine: An update
Muhamed-Kheir Taha1, Tomas Marcek2, Timothy J Chapman3
1Invasive Bacterial Infections Unit and National Reference Center for Meningococci and Haemophilus Influenzae, Institut Pasteur, Université Paris Cité, Paris, France.
Insights
Vaxelis, a Hib vaccine using PRP-OMPC conjugate, is safe and effective in infants. Recent studies confirm its immunogenicity, co-administration benefits, and interchangeability, aiding invasive Haemophilus influenzae type b disease control.
Area of Science:
- Pediatrics
- Vaccinology
- Immunology
Background:
- Invasive disease caused by Haemophilus influenzae type b (Hib) poses a significant threat to young children.
- Hib conjugate vaccines have greatly reduced disease incidence.
- The polyribosylribitol phosphate-outer membrane protein complex (PRP-OMPC) conjugate shows superior infant immunogenicity compared to other conjugates.
Purpose of the Study:
- To review recent data on Vaxelis, a hexavalent vaccine containing the PRP-OMPC conjugate.
- To address key questions regarding Vaxelis's performance in infants and its use in vaccination schedules.
- To assess the implications of Vaxelis data for invasive Hib disease control in Europe.
Main Methods:
- Review of recently published clinical studies on Vaxelis.
- Analysis of immunogenicity data after the first infant dose.
- Evaluation of co-administration and interchangeability studies.
Main Results:
- Vaxelis was well-tolerated and immunogenic in infants.
- Recent studies confirm robust immunogenicity after the first dose.
- Vaxelis demonstrates favorable outcomes when co-administered with meningococcal B vaccine and is interchangeable with other hexavalent vaccines.
Conclusions:
- Vaxelis is a safe and immunogenic option for preventing invasive Hib disease in infants.
- Updated data support the use of Vaxelis in infant vaccination schedules.
- These findings have positive implications for the ongoing control of invasive Hib disease in Europe.
Abstract:
Invasive disease caused by Haemophilus influenzae type b (Hib) is a major health concern, particularly in children under 5 years of age and vulnerable populations. Use of Hib conjugate vaccines has significantly reduced the incidence of Hib disease. Among these, the polyribosylribitol phosphate-outer membrane protein complex (PRP-OMPC) conjugate has demonstrated uniquely robust immunogenicity in infants compared to PRP conjugated to tetanus toxoid. Vaxelis, using the PRP-OMPC conjugate, was well tolerated and immunogenic as shown through the clinical development program. Additional studies that are recently published address previously open questions regarding Vaxelis, including immunogenicity after the first infant dose, co-administration with meningococcal B vaccine, and interchangeability with other hexavalent vaccines. This brief review summarizes recently published Vaxelis data, with potential implications for ongoing control of invasive Hib disease in Europe.
Related Concept Videos
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:51Vaccinations